Monthly Archives: May 2017

Studies Further Validate Safety, Efficacy and an Improved Patient Experience in Use of the C2 Cryoballoon® Ablation System for Primary Treatment of Barrett’s Esophagus

2017-05-16T21:29:57+00:00

REDWOOD CITY, Calif. – May 9, 2017 – C2 Therapeutics marked Digestive Disease Week by releasing the results of clinical studies that help further validate the utility of the C2 CryoBalloon®  Ablation System (CbAS) for ablation of Barrett’s esophagus.

C2 CryoBalloon Focal Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s esophagus with dysplasia.

Click here to see full release.

Studies Further Validate Safety, Efficacy and an Improved Patient Experience in Use of the C2 Cryoballoon® Ablation System for Primary Treatment of Barrett’s Esophagus 2017-05-16T21:29:57+00:00